ATLANTA, GA - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing novel vaccines and cancer immunotherapies, announced today that its Chairman and CEO, David Dodd, will present at the Noble Capital Markets Twenty-First Annual Emerging Growth Equity Conference (NobleCon21) on December 3, 2025, at 3:00 pm ET. The conference takes place December 2-3 at the Florida Atlantic University Executive Education Complex in Boca Raton, FL.
The presentation, titled "GeoVax Corporate Update," will provide an overview of the company's lead clinical programs. GeoVax's most advanced candidate is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials. These trials evaluate the vaccine as a primary option for immunocompromised patients, including those with hematologic cancers, as a booster for patients with chronic lymphocytic leukemia (CLL), and as a more robust, durable booster among healthy individuals previously vaccinated with mRNA vaccines. Additionally, the company is advancing Gedeptin®, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 trial for advanced head and neck cancers.
GeoVax is also developing a vaccine targeting Mpox and smallpox. Based on recent regulatory guidance, the company anticipates progressing directly to a Phase 3 clinical evaluation, bypassing Phase 1 and Phase 2 trials, which could accelerate the development timeline. The company holds a strong intellectual property portfolio with worldwide rights for its technologies and product candidates.
Interested investors and guests can attend at a discounted rate by registering here using the discount code GOVXNOBLECON. A high-definition video webcast of the presentation will be available the following day on Noble Capital Markets' Conference website at www.nobleconference.com and on Channelchek at www.channelchek.com, the investor portal created by Noble. The webcast will be archived for 90 days following the event. Senior GeoVax management will also host one-on-one meetings with registered attendees.
This presentation is significant as it offers investors and stakeholders a chance to hear directly from GeoVax's leadership about the company's progress in addressing unmet medical needs. The COVID-19 vaccine program aims to provide protection for populations where current vaccines are insufficient, while the oncology program targets hard-to-treat cancers. The potential to advance the Mpox/smallpox vaccine directly to Phase 3 underscores the company's ability to navigate regulatory pathways efficiently.
For more information about GeoVax and its clinical trials, visit the company's website at www.geovax.com.
